ERBB2 and neoplasm: From the 800 patients, we acquired the data of sex, age, pathological tumor size, pathological tumor invasion size, pT, pN, lymphatic invasion, HG, NG, ER, PgR, HER2 status, Ki-67 labeling index, histological type, pathological UICC AS, pathological AJCC PS, pathological PS-NG, procedure (breast and axillary lymph node), medication therapy (endocrine therapy, chemotherapy, and anti-HER2 therapy), radiation therapy, relapse-free survival rate, and overall survival rate (Table 1).